Skip to search formSkip to main contentSkip to account menu

Canertinib

Known as: 2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, N-[-4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide, N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

CI-1033

Broader (1)

Morpholines
Receptor Tyrosine Kinase Inhibitioncanertinib dihydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Induction of autophagy enhances apoptotic cell death via epidermal growth factor receptor inhibition by canertinib in cervical cancer cells.
2017
2017
Identification and characterization of ErbB4 kinase inhibitors for effective breast cancer therapy
Abstract The overexpression of ErbB4 is associated with aggressive disease biology and reduced the survival of breast cancer… 
2017
2017
Identifying Candidates for Breast Cancer Using Interactions of Chemicals and Proteins.
Breast cancer is one of the major cause of cancer death in women worldwide. Therefore, it is urgent to discovery novel drugs or… 
2016
2016
Tumor cell resistance against targeted therapeutics: the density of cultured glioma tumor cells enhances Stat3 activity and offers protection against the tyrosine kinase inhibitor canertinib† †The…
Tumor cell resistance to drug treatment severely limits the therapeutic success of treatment. 
2013
2013
931 GENOMIC SIGNATURE CORRELATING SENSITIVITY OF BLADDER CANCER CELL LINES TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS
2012
2012
Abstract 3864: Biological basis of pan-ErbB receptor targeting for malignant melanoma treatment
Dysregulated activation of the epidermal growth factor receptor (ErbB) family (EGFR, ErBB2, ErbB3, and ErbB4) is involved in… 
2011
2011
The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells.
2010
2010
The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U-937) cells.
2009
2009
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors
The process of drug development is expensive and time consuming, with millions of dollars spent on the testing of new chemical… 
2008
2008
Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033
Neurofibromatosis Type 1 (NF1) is characterized by the abnormal proliferation of neuroectodermal tissues and the development of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)